Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 3/20 | 0.67 |
| ▸ | CTSK | P43235 | 3/20 | 0.67 |
| ▸ | CTSH | P09668 | 1/20 | 0.66 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.63 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.55 |
| ▸ | NMBR | P28336 | 2/20 | 0.53 |
| ▸ | GRPR | P30550 | 2/20 | 0.53 |
| ▸ | MC4R | P32245 | 2/20 | 0.52 |
| ▸ | MC5R | P33032 | 2/20 | 0.52 |
| ▸ | MC3R | P41968 | 2/20 | 0.52 |
| ▸ | MC1R | Q01726 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | GIPR | P48546 | 1/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387696 | 0.95 | CTSL (0.64) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30821694 | 0.94 | CTSL (0.69) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29513768 | 0.93 | CTSL (0.62) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30574265 | 0.89 | C5AR1 (0.56) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29793968 | 0.88 | C5AR1 (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30091430 | 0.86 | CTSL (0.67) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL31694509 | 0.86 | C5AR1 (0.73) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29666481 | 0.86 | C5AR1 (0.63) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL30800876 | 0.86 | C5AR1 (0.72) | CTSLCTSSCTSKCTSHC5AR1 | |
| SCHEMBL29638083 | 0.86 | CTSL (0.67) | CTSLCTSSCTSKCTSHCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12546770-B2 | Microcapsule for detecting and/or quantitating an analyte in a sample | BLINK AG (DE) | 2026-02-10 | — | — | US | claimed |
| US-20260032018-A1 | Message processing method, device, and storage medium | ZTE CORP (CN) | 2026-01-29 | — | — | US | disclosed |
| US-12442816-B2 | Sensor body for binding and/or enriching and/or detecting an analyte in a sample | BLINK AG (DE) | 2025-10-14 | — | — | US | disclosed |
| US-12419949-B2 | Modified human cytomegalovirus proteins | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-09-23 | — | — | US | disclosed |
| EP-4557694-A1 | MESSAGE PROCESSING METHOD, AND DEVICE AND STORAGE MEDIUM | ZTE Corporation (CN) | 2025-05-21 | — | — | EP | disclosed |
| US-20250101067-A1 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-03-27 | — | — | US | disclosed |
| CN-111542754-B | Microcapsules for detecting and/or quantifying analytes in a sample | 布林克公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4469078-A1 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024011938-A1 | MESSAGE PROCESSING METHOD, AND DEVICE AND STORAGE MEDIUM | 中兴通讯股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| EP-3877054-B1 | PROCESS FOR PRODUCING GENETICALLY ENGINEERED T CELLS | JUNO THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230250142-A1 | DOCK TAG SYSTEM | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| WO-2023144665-A1 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-03 | — | — | WO | disclosed |
| US-20230201334-A1 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230181641-A1 | PROCESS FOR PRODUCING DONOR-BATCHED CELLS EXPRESSING A RECOMBINANT RECEPTOR | JUNO THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| EP-4180056-A1 | CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2023-05-17 | — | — | EP | disclosed |
| EP-4165065-A2 | GBS FERRITIN NANOPARTICLES | GlaxoSmithKline Biologicals S.A. (BE) | 2023-04-19 | — | — | EP | disclosed |
| EP-4150057-A2 | PROCESS FOR PRODUCING DONOR-BATCHED CELLS EXPRESSING A RECOMBINANT RECEPTOR | Juno Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115835873-A | Method for generating donor batch cells expressing recombinant receptor | 朱诺治疗学股份有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-3247722-B1 | CYTOMEGALOVIRUS ANTIGENS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-11-30 | — | — | EP | disclosed |
| EP-4004018-A1 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | GlaxoSmithKline Biologicals SA (BE) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260032018-A1 | Message processing method, device, and storage medium | TTN, TGOLN2, PNN | CTSL 365/4885CTSS 1579/4885CTSK 1472/4885 |
| US-12546770-B2 | Microcapsule for detecting and/or quantitating an analyte in a sample | MMP1, PGA5, AQP1 | CTSL 28/4885CTSS 128/4885CTSK 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.